Biotechnology is often associated with breakthrough moments — a new therapy, a scientific discovery, or a revolutionary medical technology. Headlines tend to celebrate these events as if innovation happens suddenly, driven by a single moment of brilliance.
In reality, biotechnology ecosystems are not built on breakthroughs alone. They are built on persistence.
Every successful biotech hub in the world has emerged through decades of incremental progress. Laboratories conduct thousands of experiments before a single promising result appears. Clinical trials test therapies across multiple stages before approval becomes possible. Investors fund numerous companies, knowing that only a fraction will ultimately succeed.
The public sees the breakthrough; the ecosystem experiences the process.
This distinction matters because emerging biotech markets sometimes expect rapid transformation. When countries announce national biotechnology strategies or launch investment initiatives, expectations rise quickly. Stakeholders anticipate immediate success, rapid commercialization, and visible global impact.
Biotechnology does not operate on that timeline. Drug development alone can take more than a decade from initial discovery to regulatory approval. Diagnostics, advanced therapeutics, and biologics manufacturing all require extensive validation, infrastructure, and regulatory engagement.
Patience is therefore not simply desirable in biotech ecosystems. It is essential.
Persistence must exist across multiple levels of the ecosystem. Scientists must remain committed to research even when experiments fail. Investors must maintain confidence during long development cycles. Governments must continue supporting infrastructure and regulatory progress even when commercial outcomes take time.
Without this persistence, promising ecosystems lose momentum before reaching maturity.
One of the defining characteristics of successful biotech hubs is institutional memory. Over time, scientists gain experience navigating clinical development, regulators refine approval frameworks, investors develop sector-specific expertise, and entrepreneurs learn how to translate science into commercial products. This accumulated knowledge compounds.
Each generation of companies benefits from the experience of those that came before. Early failures become lessons that strengthen future ventures. Scientific networks deepen, talent circulates across organizations, and investors gain confidence in the ecosystem’s long-term potential. Persistence creates credibility.
For global investors and pharmaceutical partners, credibility matters as much as capital. International partners are more likely to collaborate with ecosystems that demonstrate consistency, reliability, and regulatory maturity.
These attributes cannot be built overnight. They emerge through repeated cycles of experimentation, investment, and learning.
Every successful biotech hub in the world has emerged through decades of incremental progress
Dr. Huda Alfardus
Saudi Arabia has already taken significant steps toward building this kind of ecosystem. Investments in research institutions, life sciences infrastructure, and biotechnology strategy signal long-term commitment to the sector. But the next phase will require sustained persistence.
Biotechnology ecosystems mature through continuity. Policies must remain stable long enough for companies to plan multi-year development programs. Capital must remain available for follow-on funding rounds. Talent development programs must continue producing skilled professionals capable of operating in scientific and industrial environments.
Equally important is the willingness to learn from early experiences. The first generation of biotech companies in any ecosystem rarely produces universal success. Some ventures will fail scientifically, others commercially. What matters is not the absence of failure but the ability to extract knowledge from it.
Failure in biotechnology is often misunderstood. In reality, unsuccessful trials and abandoned technologies frequently produce valuable scientific insight. These insights inform future research directions and strengthen the capabilities of the ecosystem as a whole.
Over time, this process builds resilience. Resilient ecosystems are able to adapt as scientific understanding evolves. They shift focus toward new therapeutic areas, adopt emerging technologies, and respond to global health challenges. Persistence allows them to remain relevant even as the scientific landscape changes.
Ultimately, biotechnology ecosystems are not defined by a single discovery; they are defined by the systems that make discovery possible.
Laboratories, investors, regulators, universities, manufacturing facilities, and entrepreneurs all contribute to this system. When these components operate together over extended periods of time, the conditions for breakthrough innovation emerge naturally.
In that sense, persistence is not the opposite of innovation. It is the environment in which innovation becomes possible.
For emerging biotech ecosystems, the lesson is clear. The path to global relevance does not depend on a single transformative breakthrough. It depends on building institutions capable of supporting thousands of experiments, dozens of companies, and many years of disciplined progress.
Biotechnology rewards those who remain committed long enough to see the process through. And the ecosystems that persist are ultimately the ones that lead.
• Dr. Huda Alfardus is a businesswoman and biotech investment expert focused on innovation, venture capital, and expanding women’s participation in business and investment markets.